[Retracted] The Crucial Role of CXCL8 and Its Receptors in Colorectal Liver Metastasis

Table 1

A summary of potential new therapeutic strategies by targeting CXCL8-CXCR1/2 signaling axes alone or in combination with other treatments to control CRC progression and overcome drug resistance in colorectal cancer.

Targeting CXCL8-CXCR1/2 signaling axes alone		Combined with other treatments
Indirect targeting	Direct targeting
NSAIDs (e.g., aspirin and ibuprofen)	CXCL8/CXCR1/CXCR2 siRNA, antagonist-neutralizing antibodies, small-molecule receptor antagonists (e.g., SCH-527123 and SCH-479833)	+Immunotherapy (e.g., PD1 checkpoint blockade)
PI3K/Akt inhibitor LY294002; a Ca^2+ chelator, BAPTA-AM; ERK inhibitors U0126 and PD98059; NF-κB inhibitor		+Conventional chemotherapeutic drugs (e.g., capecitabine, oxaliplatin, and 5-FU)
		+Autophagy inhibitors/activators